Responsible implementation of expanded carrier screening

UNSCEAR (United Nations Scientific Committee on the Effects of Atomic Radiation) Hereditary effects of radiation. United Nations: New York, NY, USA, 2001.

Sankaranarayanan K : Ionizing radiation and genetic risks IX. Estimates of the frequencies of mendelian diseases and spontaneous mutation rates in human populations: a 1998 perspective. Mutat Res 1998; 411: 129–178.

Ropers HH : On the future of genetic risk assessment. J Community Genet 2012; 3: 229–236.

Morris JK, Law MR, Wald NJ : Is cascade testing a sensible method of screening a population for autosomal recessive disorders? Am J Med Genet A 2004; 128A: 271–275.

Henneman L, Borry P, Chokoshvili D et al: Responsible implementation of expanded carrier screening: Summary and recommendations of the European Society of Human Genetics. Eur J Hum Genet 2016; 24: 781–783.

Castellani C, Macek Jr M, Cassiman JJ et al: Benchmarks for cystic fibrosis carrier screening: a European consensus document. J Cyst Fibros 2010; 9: 165–178.

Castellani C, Massie J : Newborn screening and carrier screening for cystic fibrosis: alternative or complementary? Eur Respir J 2014; 43: 20–23.

Rigter T, Henneman L, Kristoffersson U et al: Reflecting on earlier experiences with unsolicited findings: points to consider for next-generation sequencing and informed consent in diagnostics. Hum Mutat 2013; 34: 1322–1328.

De Wert G, Dondorp W, Knoppers B : Preconception care and genetic risk: ethical issues. J Community Genet 2012; 3: 221–228.

Kaback MM : Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr 2000; 159 (Suppl 3): S192–S195.

Edwards JG, Feldman G, Goldberg J et al: Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the american college of medical genetics and genomics, american college of obstetricians and gynecologists, national society of genetic counselors, perinatal quality foundation, and society for maternal-fetal medicine. Obstet Gynecol 2015; 125: 653–662.

Andermann A, Blancquaert I, Beauchamp S, Dery V : Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317–319.

Nuffield Council on Bioethics Genetic Screening. Ethical Issues. Nuffield Council on Bioethics: London, UK, 1993.

Health Council of the Netherlands: Committee Genetic Screening: Genetic Screening. Health Council: The Hague, The Netherlands, 1994, Report No. 1994: 22E.

Godard B, Ten Kate L, Evers-Kiebooms G, Ayme S : Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 2003; 11 (Suppl 2): S49–S87.

Human Genetics Commission Increasing Options, Informing Choice: A Report on Preconception Genetic Testing and Screening. Human Genetics Commission: London, UK, 2011.

Grody WW, Thompson BH, Gregg AR et al: ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med 2013; 15: 482–483.

Janssens S, De Paepe A, Borry P : Attitudes of health care professionals toward carrier screening for cystic fibrosis. A review of the literature. J Community Genet 2014; 5: 13–29.

Ioannou L, Massie J, Lewis S et al: Evaluation of a multi-disease carrier screening programme in Ashkenazi Jewish high schools. Clin Genet 2010; 78: 21–31.

Darcy D, Tian L, Taylor J, Schrijver I : Cystic fibrosis carrier screening in obstetric clinical practice: knowledge, practices, and barriers, a decade after publication of screening guidelines. Genet Test Mol Biomarkers 2011; 15: 517–523.

Morgan MA, Driscoll DA, Mennuti MT, Schulkin J : Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 2004; 6: 450–455.

Poppelaars FA, Henneman L, Ader HJ et al: How should preconceptional cystic fibrosis carrier screening be provided? Opinions of potential providers and the target population. Community Genet 2003; 6: 157–165.

Qureshi N, Armstrong S, Modell B : GPs' opinions of their role in prenatal genetic services: a cross-sectional survey. Fam Pract 2006; 23: 106–110.

Poppelaars FA, Van der Wal G, Braspenning JC et al: Possibilities and barriers in the implementation of a preconceptional screening programme for cystic fibrosis carriers: a focus group study. Public Health 2003; 117: 396–403.

McClaren BJ, Delatycki MB, Collins V, Metcalfe SA, Aitken M : "It is not in my world": an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 2008; 16: 435–444.

Stark Z, Massie J, McClaren B et al: Current practice and attitudes of Australian obstetricians toward population-based carrier screening for inherited conditions. Twin Res Hum Genet 2013; 16: 601–607.

Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB : Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet 2010; 18: 1077–1083.

Jans SM, De Jonge A, Henneman L, Cornel MC, Lagro-Janssen AL : Attitudes of general practitioners and midwives towards ethnicity-based haemoglobinopathy-carrier screening. Eur J Hum Genet 2012; 20: 1112–1117.

Modell B, Petrou M, Layton M et al: Audit of prenatal diagnosis for haemoglobin disorders in the United Kingdom: the first 20 years. Br Med J 1997; 315: 779–784.

Benn P, Chapman AR, Erickson K et al: Obstetricians and gynecologists' practice and opinions of expanded carrier testing and noninvasive prenatal testing. Prenat Diagn 2014; 34: 145–152.

Metcalfe SA : Carrier screening in preconception consultation in primary care. J Community Genet 2012; 3: 193–203.

Cho D, McGowan ML, Metcalfe J, Sharp RR : Expanded carrier screening in reproductive healthcare: perspectives from genetics professionals. Hum Reprod 2013; 28: 1725–1730.

Ready K, Haque IS, Srinivasan BS, Marshall JR : Knowledge and attitudes regarding expanded genetic carrier screening among women's healthcare providers. Fertil Steril 2012; 97: 407–413.

Stoll K, Resta R : Considering the cost of expanded carrier screening panels. Genet Med 2013; 15: 318–319.

Ioannou L, McClaren BJ, Massie J et al: Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research. Genet Med 2014; 16: 207–216.

Rowley PT, Loader S, Levenkron JC : Cystic fibrosis carrier population screening: a review. Genet Test 1997; 1: 53–59.

Chen LS, Goodson P : Factors affecting decisions to accept or decline cystic fibrosis carrier testing/screening: a theory-guided systematic review. Genet Med 2007; 9: 442–450.

Conway SP, Allenby K, Pond MN : Patient and parental attitudes toward genetic screening and its implications at an adult cystic fibrosis centre. Clin Genet 1994; 45: 308–312, e-pub ahead of print 29 July 2015; doi:10.1038/ejhg.2015.160.

Janssens S, Chokoshvilli D, Binst C et al: Attitudes of cystic fibrosis patients and parents toward carrier screening and related reproductive issues. Eur J Hum Genet 2016; 24: 506–512.

Maxwell SJ, Kyne G, Molster C, Barker NM, Ormsby J, O'Leary P : Perceptions of population cystic fibrosis prenatal and preconception carrier screening among individuals with cystic fibrosis and their family members. Genet Test Mol Biomarkers 2011; 15: 159–164.

Clarke AJ : Genetic testing and genomic screening. In: Kumar D, Eng C (eds): Genomic Medicine: Principles and Practice, 2nd edn Oxford University Press: Oxford, UK, 2014, pp 224–225.

Falik-Zaccai TC, Kfir N, Frenkel P et al: Population screening in a Druze community: the challenge and the reward. Genet Med 2008; 10: 903–909.

Basel-Vanagaite L, Taub E, Drasinover V et al: Genetic carrier screening for spinal muscular atrophy and spinal muscular atrophy with respiratory distress 1 in an isolated population in Israel. Genet Test 2008; 12: 53–56.

Zlotogora J, Carmi R, Lev B, Shalev SA : A targeted population carrier screening program for severe and frequent genetic diseases in Israel. Eur J Hum Genet 2008; 17: 591–597.

Mathijssen IB, Henneman L, Van Eeten-Nijman JM et al: Targeted carrier screening for four recessive disorders: high detection rate within a founder population. Eur J Med Genet 2015; 58: 123–128.

Ekstein J, Katzenstein H : The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet 2001; 44: 297–310.

Frumkin A, Raz AE, Plesser-Duvdevani M, Lieberman S : ‘The Most Important Test You'll Ever Take’?: attitudes toward confidential carrier matching and open individual testing among modern-religious Jews in Israel. Soc Sci Med 2011; 73: 1741–1747.

Gason AA, Metcalfe SA, Delatycki MB et al: Tay Sachs disease carrier screening in schools: educational alternatives and cheekbrush sampling. Genet Med 2005; 7: 626–632.

Barlow-Stewart K, Burnett L, Proos A et al: A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. J Med Genet 2003; 40: 45.

Leib JR, Gollust SE, Hull SC, Wilfond BS : Carrier screening panels for Ashkenazi Jews: is more better? Genet Med 2005; 7: 185–190.

Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R : Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat 2010; 31: 1240–1250.

Hall J, Fiebig DG, King MT, Hossain I, Louviere JJ : What influences participation in genetic carrier testing?: results from a discrete choice experiment. J Health Econom 2006; 25: 520–537.

Borry P, Clarke A, Dierickx K : Carrier screening: look before you leap: carrier screening for type 1 Gaucher disease: difficult questions. Eur J Hum Genet 2007; 16: 139–140.

Zuckerman S, Lahad A, Shmueli A : Carrier screening for gaucher disease: Lessons for low-penetrance, treatable diseases. JAMA 2007; 298: 1281–1290.

Holtkamp KC, Van Maarle MC, Schouten MJ, Dondorp WJ, Lakeman P, Henneman L : Do people from the Jewish community prefer ancestry-based or pan-ethnic expanded carrier screening? Eur J Hum Genet 2016; 24: 171–177.

Cao A, Rosatelli MC, Monni G, Galanello R : Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 2002; 29: 305-vii.

Van Elderen T, Mutlu D, Karstanje J, Passchier J, Tibben A, Duivenvoorden HJ : Turkish female immigrants' intentions to participate in preconception carrier screening for hemoglobinopathies in the Netherlands: an empirical study. Public Health Genomics 2010; 13: 415–423.

Van der Pal SM, Van Kesteren NM, Van Wouwe JP, Van Dommelen P, Detmar SB : The attitudes and intention to participate in hemoglobinopathy carrier screening in The Netherlands among individuals from Turkish, Moroccan, and Surinamese descent. J Environ Public Health 2013; 2013: 374831.

Ahmed S, Green JM, Hewison J : Attitudes towards prenatal diagnosis and termination of pregnancy for thalassaemia in pregnant Pakistani women in the North of England. Prenat Diagn 2006; 26: 248–257.

Gitsels-van der Wal JT, Mannien J, Ghaly MM, Verhoeven PS, Hutton EK, Reinders HS : The role of religion in decision-making on antenatal screening of congenital anomalies: a qualitative study amongst Muslim Turkish origin immigrants. Midwifery 2014; 30: 297–302.

Giordano PC, Dihal AA, Harteveld CL : Estimating the attitude of immigrants toward primary prevention of the hemoglobinopathies. Prenat Diagn 2005; 25: 885–893.

Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP : Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation? Eur J Hum Genet 2009; 17: 999–1009.

Prior TW, Snyder PJ, Rink BD et al: Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 2010; 152A: 1608–1616.

Martyn M, Anderson V, Archibald A et al: Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population. BMJ Open 2013; 3: e003660.

Archibald AD, Jaques AM, Wake S, Collins VR, Cohen J, Metcalfe SA : ‘It's something I need to consider’: Decisions about carrier screening for fragile X syndrome in a population of non-pregnant women. Am J Med Genet 2009; 149: 2731–2738.

Fanos JH, Spangner KA, Musci TJ : Attitudes toward prenatal screening and testing for Fragile X. Genet Med 2006; 8: 129–133.

Ames AG, Metcalfe SA, Dalton AA, Duncan RE, Emery J : Measuring informed choice in population-based reproductive genetic screening: a systematic review. Eur J Hum Genet 2015; 23: 8–21.

Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW III, Phillips JA III : Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet 1996; 58: 617–627.

Henneman L, Bramsen I, Van Kempen L et al: Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services. Community Genet 2003; 6: 5–13.

Henneman L, Poppelaars FA, Ten Kate LP : Evaluation of cystic fibrosis carrier screening programs according to genetic screening criteria. Genet Med 2002; 4: 241–249.

Bekker H, Modell M, Denniss G et al: Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ 1993; 306: 1584–1586.

Ahmad WI, Atkin K : Primary care and haemoglobin disorders: a study of families and professionals. Crit Public Health 2000; 10: 41–53.

Dormandy E, Gulliford M, Bryan S et al: Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. Br Med J 2010; 341: c5132.

Van Agt HM, Korfage IJ, Essink-Bot ML : Interventions to enhance informed choices among invitees of screening programmes-a systematic review. Eur J Public Health 2014; 24: 789–801.

Canatan D, Aydinok Y, Kilinc Y et al: National thalassemia prevention campaign: the talotir project. Turk J Haematol 2013; 30: 91–92.

Canatan D, Kose MR, Ustundag M, Haznedaroglu D, Ozbas S : Hemoglobinopathy control program in Turkey. Community Genet 2006; 9: 124–126.

Saffi M, Howard N : Exploring the effectiveness of mandatory premarital screening and genetic counselling programmes for beta-thalassaemia in the Middle East: a scoping review. Publ Health Genomics 2015; 18: 193–203.

Karimi M, Jamalian N, Yarmohammadi H, Askarnejad A, Afrasiabi A, Hashemi A : Premarital screening for beta-thalassaemia in Southern Iran: options for improving the programme. J Med Screen 2007; 14: 62–66.

Alswaidi FM, O'Brien SJ : Premarital screening programmes for haemoglobinopathies, HIV and hepatitis viruses: review and factors affecting their success. J Med Screen 2009; 16: 22–28.

Srinivasan BS, Evans EA, Flannick J et al: A universal carrier test for the long tail of Mendelian disease. Reprod Biomed Online 2010; 21: 537–551.

Bell CJ, Dinwiddie DL, Miller NA et al: Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 2011; 3: 65ra4.

Sikkema-Raddatz B, Johansson LF, de Boer EN et al: Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat 2013; 34: 1035–1042.

Linderman MD, Brandt T, Edelmann L et al: Analytical validation of whole exome and whole genome sequencing for clinical applications. BMC Med Genomics 2014; 7: 20.

Brownstein CA, Beggs AH, Homer N et al: An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol 2014; 15: R53.

Weiss MM, Van der Zwaag B, Jongbloed JD et al: Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of Dutch genome diagnostic laboratories. Hum Mutat 2013; 34: 1313–1321.

Peterlin B, Vidmar L, Borry P et al: Expanded carrier screening tests currently on the commercial market. Eur J Hum Genet 2014; 22 (Suppl 1): 291.

Kingsmore S : Comprehensive carrier screening and molucular diagnostic testing for recessive childhood diseases. PLoS Curr 2012; e4f9877ab8ffa9.

Orphanet. Prevalence and incidence of rare diseases: Bibilographic data. Orphanet Report Series 2015, http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf Last accessed 18 August 2015.

Lazarin GA, Haque IS, Nazareth S et al: An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med 2013; 15: 178–186.

Francioli LC, Menelaou A, Puli SL et al: Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet 2014; 46: 818–825.

Stenson PD, Mort M, Ball EV et al: The Human Gene Mutation Database: 2008 update. Genome Med 2009; 1: 13.

Borry P, Henneman L, Lakeman P, Ten Kate LP, Cornel MC, Howard HC : Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. Hum Reprod 2011; 26: 972–977.

European Association for the Study of the Liver: EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53: 3–22.

Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS : Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328–343.

Dondorp W, De Wert G, Bombard Y et al: Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 2015; 23: 1438–1450.

Wertz DC, Knoppers BM : Serious genetic disorders: can or should they be defined? Am J Med Genet 2002; 108: 29–35.

Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS : Systematic classification of disease severity for evaluation of expanded carrier screening panels. PLoS One 2014; 9: e114391.

Anheim M, Elbaz A, Lesage S et al: Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78: 417–420.

Sherman S, Pletcher BA, Driscoll DA : Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005; 7: 584–587.

Schwartz B : The Paradox of Choice. Why More is Less. HarperCollins Publishers: New York, NY, USA, 2004.

Elias S, Annas GJ : Generic consent for genetic screening. N Engl J Med 1994; 330: 1611–1613.

Dondorp WJ, De Wert GM : The 'thousand-dollar genome': an ethical exploration. Eur J Hum Genet 2013; 21 (Suppl 1): S6–S26.

Hewison J : Psychological aspects of individualized choice and reproductive autonomy in prenatal screening. Bioethics 2015; 29: 9–18.

Axworthy D, Brock DJ, Bobrow M, Marteau TM : Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up. UK Cystic Fibrosis Follow-Up Study Group. Lancet 1996; 347: 1443–1446.

Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP : Three-month follow-up of Western and non-Western participants in a study on preconceptional ancestry-based carrier couple screening for cystic fibrosis and hemoglobinopathies in the Netherlands. Genet Med 2008; 10: 820–830.

Ioannou L, Massie J, Collins V, McClaren B, Delatycki MB : Population-based genetic screening for cystic fibrosis: attitudes and outcomes. Public Health Genomics 2010; 13: 449–456.

Mennie ME, Compton ME, Gilfillan A et al: Prenatal screening for cystic fibrosis: psychological effects on carriers and their partners. J Med Genet 1993; 30: 543–548.

Wald NJ : Couple screening for cystic fibrosis. Lancet 1991; 338: 1318–1319.

Metcalfe S, Jacques A, Archibald A et al: A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genet Med 2008; 10: 525–535.

Cousens NE, Gaff CL, Delatycki MB, Metcalfe SA : Prenatal beta-thalassemia carrier screening in Australia: healthcare professionals' perspectives of clinical practice. Prenat Diagn 2014; 34: 246–250.

Cousens N, Gaff C, Metcalfe S, Delatycki M : He didn't say that thalassaemia might come up. Beta-thalassaemia carriers' experiences and attitudes. J Community Genet 2013; 4: 223–232.

Marteau TM, van DM, Ellis I : Effects of genetic screening on perceptions of health: a pilot study. J Med Genet 1992; 29: 24–26.

Henneman L, Bramsen I, Van der Ploeg HM, Ten Kate LP : Preconception cystic fibrosis carrier couple screening: impact, understanding, and satisfaction. Genetic Testing 2002; 6: 195–202.

Payne Y, Williams M, Cheadle J et al: Carrier screening for cystic fibrosis in primary care: evaluation of a project in South Wales. The South Wales Cystic Fibrosis Carrier Screening Research Team. Clin Genet 1997; 51: 153–163.

Gordon C, Walpole I, Zubrick SR, Bower C : Population screening for cystic fibrosis: knowledge and emotional consequences 18 months later. Am J Med Genet A 2003; 120A: 199–208.

Raz AE, Vizner Y : Carrier matching and collective socialization in community genetics: Dor Yeshorim and the reinforcement of stigma. Soc Sci Med 2008; 67: 1361–1369.

Markel H : The stigma of disease: implications of genetic screening. Am J Med 1992; 93: 209215.

Kenen RH, Schmidt RM : Stigmatization of carrier status: social implications of heterozygote genetic screening programs. Am J Public Health 1978; 68: 1116–1120.

Lakeman P, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP : Developing and optimizing a decisional instrument using self-reported ancestry for carrier screening in a multi-ethnic society. Genet Med 2006; 8: 502–509.

Delatycki MB, Wolthuizen M, Collins V et al: IronXS: high-school screening for hereditary haemochromatosis is acceptable and feasible. Eur J Hum Genet 2012; 20: 505–509.

Fears R, Ter Meulen V, EASAC–FEAM Working Group: The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 2013; 21: 703–707.